Shigemasa Katayama
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
An observational study on the effects of as-needed use of various antipsychotic drugs for agitation due to psychotic disorders.
Journal: International clinical psychopharmacology
Published: January 29, 2026
Enhanced treatment outcomes for schizophrenia through combined long-acting injectable antipsychotic medications and home visits: retrospective cohort study.
Journal: BJPsych open
Published: August 15, 2025
Service contents and recovery orientation of psychiatric home-visit nursing evaluated by users in Japan.
Journal: Global health & medicine
Published: March 31, 2023
Future perspective of psychiatric home-visit nursing provided by nursing stations in Japan.
Journal: Global health & medicine
Published: March 31, 2023
Real-world effectiveness of antipsychotic treatments in 1011 acutely hospitalized patients with schizophrenia: A one-year follow-up study.
Journal: Asian journal of psychiatry
Published: August 30, 2021
Victimization In Childhood Affects Depression In Adulthood Via Neuroticism：A Path Analysis Study.
Journal: Neuropsychiatric disease and treatment
Published: June 21, 2019
Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia.
Journal: Asian journal of psychiatry
Published: January 29, 2019
Influence of trait anxiety, child maltreatment, and adulthood life events on depressive symptoms.
Journal: Neuropsychiatric disease and treatment
Published: December 21, 2018
A prospective naturalistic multicenter study on choice of parenteral medication in psychiatric emergency settings in Japan.
Journal: Neuropsychopharmacology reports
Published: January 12, 2018
Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Journal: Schizophrenia research
Published: February 20, 2014
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
Journal: Psychiatry research
Published: July 17, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026